AdAlta reports positive progress on partnering initiatives at key January conferences

AdAlta Limited (ASX: $1AD) has made significant strides in advancing its AD-214 and i-CAR cell therapy partnering programs during the JPMorgan Healthcare Conference and Advanced Therapies Week. The company also announced the completion of the AD-214 Phase I extension study, with final results expected by the end of February 2024.

Executive commentary on partnering initiatives and progress

AdAlta's CEO and Managing Director, Tim Oldham, expressed satisfaction with the progress made in January towards AD-214 partnering goals and the positive reception of the i-CAR-T cell therapy strategy. He emphasized the considerable upside potential for shareholders if the partnering initiatives are successful, while refraining from making forecasts about their ultimate value.

Summary of AdAlta's partnering progress and outlook

AdAlta has actively engaged in partnering activities at key industry conferences, with a focus on securing financing for Phase II clinical studies of AD-214 and establishing new co-development collaborations for i-body-enabled i-CAR-T therapies. The completion of the AD-214 Phase I extension study marks a significant milestone, with final results expected to support partnering by the end of February 2024. The company's i-CAR-T strategy has received positive feedback, indicating the potential to develop a valuable clinical stage pipeline of assets beyond AD-214. AdAlta's ambitions to enable advanced cell and gene therapy products reflect its commitment to addressing challenging medical conditions and maximizing the potential of its i-body® technology platform.